Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GPR3 | P46089 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 3/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30527184 | 0.75 | CYP1A2 (0.60) | KDM4EGPR3EGFRALDH1A1MAPT | |
| SCHEMBL1672650 | 0.75 | CYP1A2 (0.60) | KDM4EGPR3EGFRALDH1A1MAPT | |
| SCHEMBL30198446 | 0.75 | CYP1A2 (0.60) | KDM4EGPR3EGFRALDH1A1MAPT | |
| SCHEMBL6615577 | 0.74 | KDM4E (0.46) | KDM4EGPR3EGFRALDH1A1MAPT | |
| SCHEMBL17871059 | 0.71 | KDM4E (0.46) | KDM4EGPR3EGFRALDH1A1MAPT | |
| SCHEMBL329760 | 0.71 | KDM4E (0.46) | KDM4EGPR3EGFRALDH1A1MAPT | |
| SCHEMBL1748568 | 0.71 | KDM4E (0.46) | KDM4EGPR3EGFRALDH1A1MAPT | |
| SCHEMBL277638 | 0.71 | KDM4E (0.46) | KDM4EGPR3EGFRALDH1A1MAPT | |
| SCHEMBL7900625 | 0.71 | KDM4E (0.52) | KDM4EGPR3EGFRALDH1A1MAPT | |
| SCHEMBL13911016 | 0.71 | CYP1A2 (0.56) | KDM4EGPR3EGFRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | claimed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | claimed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | claimed |
| WO-2019243550-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2019-12-26 | — | — | WO | claimed |
| US-20090137567-A1 | Methods for Treating Blood Disorders | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | claimed |
| EP-2023913-A2 | METHODS FOR TREATING BLOOD DISORDERS | Colorado State University Research Foundation (US) | 2009-02-18 | — | — | EP | claimed |
| US-20080075692-A1 | prophylaxis of blood disorder such as sickle cell anemia, beta -thalassemia, neutropenia or thrombocytopenia, comprising administering carboxylic acids, that stimulates production of fetal hemoglobin, hematopoiesis, erythropoiesis, myelopoiesis and neutrophil production | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2008-03-27 | — | — | US | claimed |
| WO-2007133653-A2 | METHODS FOR TREATING BLOOD DISORDERS | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2007-11-22 | — | — | WO | claimed |
| US-6908926-B1 | Substituted imidazoles, their preparation and use | NOVO NORDISK A/S (DK) | 2005-06-21 | — | — | US | claimed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| EP-4371979-A1 | FORMAMIDE DERIVATIVE AND AGRICULTURAL OR HORTICULTURAL PLANT DISEASE CONTROL AGENT | Kumiai Chemical Industry Co., Ltd. (JP) | 2024-05-22 | — | — | EP | disclosed |
| CN-117693500-A | Carboxamide derivative and agricultural/horticultural plant disease control agent | 组合化学工业株式会社 | 2024-03-12 | — | — | CN | disclosed |
| WO-2024043261-A1 | AZO COMPOUND OR SALT THEREOF, AND POLARIZING FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE COMPRISING SAME | 日本化薬株式会社 | 2024-02-29 | — | — | WO | disclosed |
| CN-114026199-B | Polarized light emitting film, polarized light emitting panel and display device containing water-soluble coumarin compound or salt thereof | 日本化药株式会社 | 2023-12-26 | — | — | CN | disclosed |
| WO-2000055143-A1 | OXAZOLONE DERIVATIVES AND THEIR USE AS ALPHA-1 ADRENORECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-21 | — | — | WO | disclosed |
| US-5798362-A | USEFUL AS ALPHA-ADRENORECEPTOR BLOCKERS; CONDENSATION | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1998-08-25 | — | — | US | disclosed |
| US-5798362-A | USEFUL AS ALPHA-ADRENORECEPTOR BLOCKERS; CONDENSATION | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1998-08-25 | — | — | US | disclosed |
| EP-0750614-A1 | QUINAZOLINYL-AMINO DERIVATIVES HAVING ALPHA-ANTAGONIST ACTIVITY | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1997-01-02 | — | — | EP | disclosed |
| WO-1995025726-A1 | QUINAZOLINYL-AMINO DERIVATIVES HAVING α-ANTAGONIST ACTIVITY | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1995-09-28 | — | — | WO | disclosed |
| EP-0624582-A1 | Substituted benzodioxine, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1994-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | KDM4E 3965/4885GPR3 2310/4885EGFR 2809/4885 |
| US-20090137567-A1 | Methods for Treating Blood Disorders | HBB, HBG1, HBG2 | KDM4E 3792/4885GPR3 4692/4885EGFR 4879/4885 |
| US-20080075692-A1 | prophylaxis of blood disorder such as sickle cell anemia, beta -thalassemia, neutropenia or thrombocytopenia, comprising administering carboxylic acids, that stimulates production of fetal hemoglobin, hematopoiesis, erythropoiesis, myelopoiesis and neutrophil production | HBG1, HBG2, HBB | KDM4E 4882/4885GPR3 2447/4885EGFR 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.